Venomyx Therapeutics is a privately held biotech company based in La Jolla, California. The company is focused on producing a recombinant antivenom that will make treatment safer, more effective, portable and affordable for snakebite victims.
Venomyx's lead product candidate, Vipax is aimed to be a broad spectrum antivenom that works for all medically relevant species. It will release four iterations of Vipax for the regions of Asia, Africa, South America, and the U.S. It also is meant to be safe, with low or no side effects, and portable (similar to an EpiPen). The company aims to manufacture its product at scale using microbial fermentation.
The company is also applying its technology to develop novel bacterial anti-toxins. It is targeting antibiotic resistant strains, such as MRSA, as well as those of interest to biodefense, such as Anthrax. The technology aims to target the toxin secreted by bacteria, thereby circumventing antibiotic resistance.
Daniel T. Dempsey
Founder & CEO
Co-Founder & COO
Director of Business Development
Director of Scientific Research
An Interview With Daniel Dempsey of Venomyx Therapeutics - IndieBio
Documentaries, videos and podcasts
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.